These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 10955373)

  • 21. Proportion of oxidized LDL relative to plasma apolipoprotein B does not change during statin therapy in patients with heterozygous familial hypercholesterolemia.
    van Tits LJ; van Himbergen TM; Lemmers HL; de Graaf J; Stalenhoef AF
    Atherosclerosis; 2006 Apr; 185(2):307-12. PubMed ID: 16005883
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial.
    Stein EA; Gipe D; Bergeron J; Gaudet D; Weiss R; Dufour R; Wu R; Pordy R
    Lancet; 2012 Jul; 380(9836):29-36. PubMed ID: 22633824
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and Safety of Pitavastatin in Japanese Male Children with Familial Hypercholesterolemia.
    Harada-Shiba M; Arisaka O; Ohtake A; Okada T; Suganami H;
    J Atheroscler Thromb; 2016; 23(1):48-55. PubMed ID: 25891210
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of triple therapy (fluvastatin-bezafibrate-cholestyramine) for severe familial hypercholesterolemia.
    Leitersdorf E; Muratti EN; Eliav O; Peters TK
    Am J Cardiol; 1995 Jul; 76(2):84A-88A. PubMed ID: 7604807
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Pravastatin increases the activity pf the LDL receptors in lymphocytes of individuals with heterozygous familial hypercholesterolemia].
    Alvarez-Sala LA; Mata P; Blázquez E; Garrido JA; Ordovás JM; Rubio MJ; de Oya M
    Rev Clin Esp; 1997 May; 197(5):317-22. PubMed ID: 9280964
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reduction of serum cholesterol in heterozygous patients with familial hypercholesterolemia. Additive effects of compactin and cholestyramine.
    Mabuchi H; Sakai T; Sakai Y; Yoshimura A; Watanabe A; Wakasugi T; Koizumi J; Takeda R
    N Engl J Med; 1983 Mar; 308(11):609-13. PubMed ID: 6828091
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Presence and type of low density lipoprotein receptor (LDLR) mutation influences the lipid profile and response to lipid-lowering therapy in Brazilian patients with heterozygous familial hypercholesterolemia.
    Santos PC; Morgan AC; Jannes CE; Turolla L; Krieger JE; Santos RD; Pereira AC
    Atherosclerosis; 2014 Mar; 233(1):206-10. PubMed ID: 24529145
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cholesterol efflux mediators in homozygous familial hypercholesterolemia patients on low-density lipoprotein apheresis.
    Nenseter MS; Narverud I; Græsdal A; Bogsrud MP; Aukrust P; Retterstøl K; Ose L; Halvorsen B; Holven KB
    J Clin Lipidol; 2013; 7(2):109-16. PubMed ID: 23415429
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cholesterol-lowering effect of NK-104, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, in guinea pig model of hyperlipidemia.
    Aoki T; Yamazaki H; Suzuki H; Tamaki T; Sato F; Kitahara M; Saito Y
    Arzneimittelforschung; 2001; 51(3):197-203. PubMed ID: 11304935
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of rs3846662 and HMGCR alternative splicing in statin efficacy and baseline lipid levels in familial hypercholesterolemia.
    Leduc V; Bourque L; Poirier J; Dufour R
    Pharmacogenet Genomics; 2016 Jan; 26(1):1-11. PubMed ID: 26466344
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical efficacy and safety of cerivastatin in the treatment of heterozygous familial hypercholesterolemia.
    Mabuchi H; Koizumi J; Kajinami K
    Am J Cardiol; 1998 Aug; 82(4B):52J-55J. PubMed ID: 9737647
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of coadministration of rosuvastatin, ezetimibe, and colestimide in heterozygous familial hypercholesterolemia.
    Kawashiri MA; Nohara A; Noguchi T; Tada H; Nakanishi C; Mori M; Konno T; Hayashi K; Fujino N; Inazu A; Kobayashi J; Mabuchi H; Yamagishi M
    Am J Cardiol; 2012 Feb; 109(3):364-9. PubMed ID: 22112743
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
    Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
    Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of low-density lipoprotein apheresis on kinetics of apolipoprotein B in heterozygous familial hypercholesterolemia.
    Maugeais C; Ouguerram K; Frénais R; Maugère P; Charbonnel B; Magot T; Krempf M
    J Clin Endocrinol Metab; 2001 Apr; 86(4):1679-86. PubMed ID: 11297603
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and Safety of Alirocumab in Japanese Patients With Heterozygous Familial Hypercholesterolemia or at High Cardiovascular Risk With Hypercholesterolemia Not Adequately Controlled With Statins　- ODYSSEY JAPAN Randomized Controlled Trial.
    Teramoto T; Kobayashi M; Tasaki H; Yagyu H; Higashikata T; Takagi Y; Uno K; Baccara-Dinet MT; Nohara A
    Circ J; 2016 Aug; 80(9):1980-7. PubMed ID: 27452202
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of long-term ezetimibe/simvastatin treatment in patients with familial hypercholesterolemia.
    Avellone G; Di Garbo V; Guarnotta V; Scaglione R; Parrinello G; Purpura L; Torres D; Campisi D
    Int Angiol; 2010 Dec; 29(6):514-24. PubMed ID: 21173733
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study Group.
    Mabuchi H; Koizumi J; Shimizu M; Kajinami K; Miyamoto S; Ueda K; Takegoshi T
    Am J Cardiol; 1998 Dec; 82(12):1489-95. PubMed ID: 9874053
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial.
    Thomas GS; Cromwell WC; Ali S; Chin W; Flaim JD; Davidson M
    J Am Coll Cardiol; 2013 Dec; 62(23):2178-84. PubMed ID: 24013058
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial.
    Raal FJ; Stein EA; Dufour R; Turner T; Civeira F; Burgess L; Langslet G; Scott R; Olsson AG; Sullivan D; Hovingh GK; Cariou B; Gouni-Berthold I; Somaratne R; Bridges I; Scott R; Wasserman SM; Gaudet D;
    Lancet; 2015 Jan; 385(9965):331-40. PubMed ID: 25282519
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hypolipidemic treatment of heterozygous familial hypercholesterolemia: a lifelong challenge.
    Vuorio AF; Kovanen PT; Gylling H
    Expert Rev Cardiovasc Ther; 2004 May; 2(3):405-15. PubMed ID: 15151486
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.